More than half of malignant gliomas reportedly have alterations in the p53 tumor suppressor gene. Because p53 plays a key role in the cellular response to DNA-damaging agents, we investigated the role of p53 gene therapy before ionizing radiation in cultured human glioma cells containing normal or mutated p53. Three established human glioma cell lines expressing the wild-type (U87 MG, p53 wt ) or mutant (A172 and U373 MG, p53 mut ) p53 gene were transduced by recombinant adenoviral vectors bearing human p53 (Adp53) and Escherichia coli ␤-galactosidase genes (AdLacZ, control virus) before radiation (0 -20 Gy). Changes in p53, p21, and Bax expression were studied by Western immunoblotting, whereas cell cycle alterations and apoptosis were investigated by flow cytometry and nuclear staining. Survival was assessed by clonogenic assays. Within 48 hours of Adp53 exposure, all three cell lines demonstrated p53 expression at a viral multiplicity of infection of 100. p21, which is a p53-inducible downstream effector gene, was overexpressed, and cells were arrested in the G 1 phase. Bax expression, which is thought to play a role in p53-induced apoptosis, did not change with either radiation or Adp53. Apoptosis and survival after p53 gene therapy varied. U87 MG (p53 wt ) cells showed minimal apoptosis after Adp53, irradiation, or combined treatments. U373 MG (p53 mut ) cells underwent massive apoptosis and died within 48 hours of Adp53 treatment, independent of irradiation. Surprisingly, A172 (p53 mut ) cells demonstrated minimal apoptosis after Adp53 exposure; however, unlike U373 MG cells, apoptosis increased with radiation dose. Survival of all three cell lines was reduced dramatically after Ͼ10 Gy. Although Adp53 transduction significantly reduced the survival of U373 MG cells and inhibited A172 growth, it had no effect on the U87 MG cell line. Transduction with AdLacZ did not affect apoptosis or cell cycle progression and only minimally affected survival in all cell lines. We conclude that responses to p53 gene therapy are variable among gliomas and most likely depend upon both cellular p53 status and as yet ill-defined downstream pathways involving activation of cell cycle regulatory and apoptotic genes.
M
utations of the p53 tumor suppressor gene have been reported in more than half of all human cancers, including brain, lung, breast, prostate, thyroid, bladder, colon, liver, leukemia, head and neck, and ovarian cancers.
1,2 p53 may play a central role in cell cycle regulation, DNA repair, and programmed cell death after DNA damage. Alteration of its function can also lead to genomic instability, which is thought to be an early event in glioma oncogenesis. 3 Normal p53 function is important in the cellular response to genotoxic agents causing DNA damage. The p53 protein acts as a transcription factor, inducing growth arrest by modulating specific downstream target genes, including p21, which arrests cells in late G 1 by inhibiting cyclin-dependent kinase activity, 4, 5 or by up-regulating GADD45, which inhibits DNA synthesis and may activate nucleotide excision repair. 6 Alternatively, p53-mediated regulation of apoptosis is not well understood, and some evidence implies that transactivation of the bax gene (a member of the Bcl-2 family that, in contrast with Bcl-2, has the ability to induce apoptosis) plays a role. 7 Loss of these p53-dependent regulatory functions may, therefore, lead to tumor radioresistance and account for the association between p53 mutations and the poorer prognosis observed in some tumors.
Despite recent advances in p53 biology, the relationship between p53 gene expression and cellular radiosensitivity remains unclear. Reports of increased, decreased, and no apparent differences in radiosensitivities have all been associated with p53 function. 8 -10 In a normal cell, irradiation or other DNA-damaging agents can induce a p53-dependent cell cycle arrest, which presumably allows enough time to repair the damaged cellular genome. Alternatively, if DNA damage is beyond repair, p53-dependent apoptosis may serve a protective role and prevent the transfer of new mutations to daughter cells. In a neoplastic cell bearing the wild-type (wt) p53 gene, however, such a response could have both beneficial and harmful therapeutic consequences. After DNA damage (chemotherapy or irradiation), p53-dependent G 1 arrest could confer therapeutic resistance by providing tumor cells with enough time to undergo DNA repair before cell division. Conversely, p53-dependent apoptosis could confer therapeutic sensitivity to the tumor cells. In a neoplastic cell bearing a nonfunctional p53 gene, the opposite may be true: cells may become sensitive by not arresting in G 1 for repair or may become resistant by averting the apoptosis induced by irradiation or chemotherapy. An overexpression of p53 by gene therapy techniques may, therefore, have both beneficial and harmful therapeutic consequences and may depend upon the cell type and endogenous nature of p53 and other cell cycle and apoptotic regulatory genes.
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Although the antineoplastic role of p53 gene therapy has been documented in various tumor models, its effect on the radiosensitization of gliomas has not been studied thoroughly. Adenoviral vectors encoding the human p53 gene (Adp53) have been used to significantly inhibit p53 mut gliomas cells in vitro and in vivo. [12] [13] [14] [15] When tested on p53 wt gliomas, however, Adp53 induced only a slight growth inhibition. 15, 16 This lack of response in p53 wt tumors may prove to be a significant limitation in a clinical application of p53 gene therapy. Because p53 is thought to be a mediator of radiation-induced apoptosis, we hypothesized that its overexpression may lead to the sensitization of both p53 mut -and also p53 wt -bearing gliomas.
In this study, Adp53 was used to transfer the wt human p53 gene into human glioma cell lines with differing p53 functions before radiation. Although p53 overexpression led to apoptosis and/or radiosensitization of p53 mut cell lines (U373 MG and A172), it had little effect in p53 wt -expressing cells (U87 MG).
MATERIALS AND METHODS

Cell culture and adenoviral vectors
The human glioma cell lines U87 MG, A172, and U373 MG were obtained from the American Type Culture Collection (Manassas, Va) and grown in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum (Life Technologies, Gaithersburg, Md), penicillin G (100 U/mL), and streptomycin (100 g/mL) at 37°C. These cell lines were selected because of their known p53 gene status and efficient transduction with adenoviruses. U87 MG expresses wt p53, whereas A172 and U373 MG express mutant forms. 15 Adenoviral vector propagation and isolation have been described previously. 12 The adenoviral vector AdHCMVsp1LacZ (AdLacZ) contains an expression cassette encoding the Escherichia coli ␤-galactosidase gene, driven by the immediate early cytomegalovirus promoter upstream from a polyadenylation signal. This vector served as a control in our experiments and was used to confirm the transduction efficiencies of the glioma cell lines as reported by other investigators. 15 Adp53 has a similar construction, except that it contains a 1.4-kilobase pair sequence encoding the human wt p53 protein instead of the ␤-galactosidase gene.
In vitro gene delivery
In vitro transduction was performed as described previously. 17 Briefly, nonconfluent monolayers in six-well plates were incubated in 1.5 mL of sera-free culture medium with or without the vectors (i.e., AdLacZ or Adp53) at a multiplicity of infection of 100 for 60 minutes at 37°C. After this incubation, 1.5 mL of medium containing 10% fetal calf serum was added to each plate. Some cells were then irradiated 4 hours later at different intensities using a 137 Cs irradiator (Sheppard, Glendale, Calif) at a dose rate of 5.94 Gy/min. Other mockirradiated cells were treated in a similar manner without ionizing radiation. Cells were then collected by trypsinization after 48 hours and stained for flow cytometry as described below.
Flow cytometry
At 48 hours after irradiation, adherent cells were harvested by trypsinization and resuspended with the floating cells in 10 mM tris(hydroxymethyl)aminomethane (Tris) (pH 7.0) and 150 mM NaCl (Tris saline). After several washings, cells were centrifuged and resuspended in 1 mL of fixative solution (100 L of Tris saline and 900 L of absolute ethanol) and stored at Ϫ20°C. Before flow cytometry, cells were washed and incubated for 15 minutes in phosphate citric acid buffer (0.192 M Na 2 HPO 4 and 4 mM citric acid) and then resuspended in propidium iodine (PI) solution (50 g/mL PI, 1 mg/mL ribonuclease A, 10 mM ethylenediaminetetraacetic acid, and 0.2% Nonidet P-40 in phosphate-buffered saline (PBS)). Cells were incubated in the dark for 1 hour at 4°C and then analyzed with a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, Calif) equipped with a 15-mW, 488-nm air-cooled argon ion laser. At least 10,000 events were acquired using Lysis II software (Becton Dickinson). Orange fluorescence (PI, FL2) was collected using a 585 Ϯ 42-nm BP filter, and DNA content was measured using FL2 area versus FL2 width for doublet discrimination. Data were analyzed using Modfit software (Verity Software House, Topsham, Me). Each experiment was performed in triplicate and repeated at least twice.
Western blotting
Both adherent and floating cells were collected as described above, washed in PBS, and lysed in RIPA buffer (37.5 mM NaCl, 12.5 mM Tris base, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 10 L/mL of phenylmethylsulfonyl fluoride, aprotinin, leupeptin, and pepstatin) at 4°C for 30 minutes. Lysates were centrifuged at 10,000 ϫ g for 15 minutes, sample protein concentrations were defined spectrophotometrically using a bovine serum albumin protein assay (Pierce, Rockford, Ill), and a 50-g aliquot of total protein was separated in 10% (for p53 and p21) or 15% (for Bax) SDS-polyacrylamide gel electrophoresis under reducing conditions after a 3-minute boil in SDS sample buffer. Gels were then electroblotted onto Immobilon-P transfer membranes (Millipore, Bedford, Mass). After blocking for nonspecific binding with 5% milk and 0.05% Tween-20 in PBS, membranes were incubated with either mouse monoclonal anti-human p53 antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif), anti-human p21 WAF1 antibodies (Oncogene Science, Uniondale, NY), or polyclonal anti-human Bax antibodies (Santa Cruz Biotechnology) as recommended by the supplier. Horseradish peroxidase-conjugated goat anti-mouse IgG antibody was then used to visualize the protein signal using SuperSignal chemiluminescent substrate (Pierce).
Hoechst staining for apoptotic cells
Cells in monolayers were washed in PBS and fixed (150 mL methanol and 50 mL glacial acetic acid) for Ն2 hours at 4°C before incubating them with freshly made Hoechst 33258 stain (10 g/mL in PBS, Sigma, St. Louis, Mo). The stain was removed after a 15-minute incubation, and cells were washed with PBS and visualized with a fluorescent microscope under N-propyl gallate (0.1 M solution in 80% glycerol).
Clonogenic survival assays
After treatments with various vectors and/or radiation (as indicated), cells were harvested by trypsinization, replated at a density of 3000 cells/100-mm Petri dish in triplicate, and grown under the above culture conditions. After 2 weeks, plates were washed with PBS, fixed, and stained with Coomassie blue. The number of colonies containing Ͼ50 normal-appearing cells was counted.
RESULTS
p53, p21, and Bax expression Consistent with other reports, 15 all three cell lines demonstrated Ն80% transduction with AdLacZ at a multiplicity of infection of 100 (data not shown). Effective viral transduction was also confirmed by the elevation of p53 in all cell lines within 48 hours of Adp53 exposure (Fig 1, lanes 1 and 6) . Neither radiation nor AdLacZ had any effect on endogenous or exogenous p53 expression (Fig 1, lanes 2-4 and 7-9) .
The biological activity of exogenous p53 was tested by examining cellular p21 content, which is a known p53-inducible cell cycle regulator. 4 p53 overexpression led to elevations in p21 protein in all three cell lines, suggesting intact p53 transcriptional activity (Fig 1) . Although X-radiation had no effect on p21 levels in transduced cells, it slightly increased endogenous p21 expression by A172 and U87 MG cells, suggesting the presence of p53-independent mechanisms in regulating this protein. 18 Because Bax has been suggested to play a role in p53-mediated apoptosis, 7 we examined its expression in all three cell lines and found little change in its steadystate protein levels after radiation or Adp53 treatments.
Apoptosis
Nuclear fragmentation suggestive of apoptosis was most evident in Adp53-exposed U373 MG cells (Fig 2A) and in A172 cells receiving combined treatment (data not shown). Flow cytometry was used to quantitate apoptosis by measuring the sub-G 1 cell population. Regardless of irradiation dose, p53 gene therapy induced profound apoptosis in U373 MG cells (Fig 3) , so that all cells died within 48 hours of transduction. Alternatively, Adp53 induced only low levels of apoptosis in A172 cells when administered alone; however, when given before radiation, Adp53 significantly increased cell death (Fig 3) . In contrast, U87 MG cells showed mild apoptosis with Adp53, radiation, or combined treatment. In every cell line, AdLacZ had mild cytopathic effects and nuclear fragmentation.
Cell cycle
The effect of ionizing radiation and p53 gene therapy on cell cycle distribution was examined by flow cytometry (Fig 4) . Within 48 hours of irradiation (20 Gy), a 3-to 6-fold increase in G 2 /M cells was noted in U87 MG and U373 MG cells (Fig 5, A and B, respectively) . This G 2 /M checkpoint most likely represented a p53-independent mechanism, because U373 MG cells express a mutant p53 protein and U87 MG cells did not demonstrate elevations in p53 protein after X-radiation. Alternatively, A172 cells demonstrated mild G 1 arrest after irradiation (Fig 5C) . This G 1 arrest may have been mediated by elevations in p21 protein, which functions as a G 1 checkpoint regulator 5 and was elevated in this cell line after irradiation (Fig 1) . Because A172 cells have a mutation in the p53 gene, this observation supports the presence of other p53-independent G 1 arrest mechanisms, possibly working through p21. 18 The effect of p53 gene therapy on cell cycle regulation was evident in all three cell lines. A 30% increase in G 1 arrest was noted in A172 cells after Adp53 treatment, and this increase did not change with the addition of radiation (Figs 4 and 5C ). In U87 MG and U373 MG cells, Adp53 did not increase G 1 arrest by itself. However, when administered before radiation, Adp53 did increase the G 1 cells by 2-to 4-fold (Fig 4 and Fig 5, A  and B ). This observation is most likely due to Adp53-mediated p21 expression, which plays a role in cell cycle regulation after radiation.
Survival
Clonogenic assays were used to examine the long-term significance of the observed apoptosis and cell cycle changes before and after the treatments described above. Adp53 transduction reduced the survival of U373 MG and A172 cells by 90% and 60%, respectively, but did not effect the U87 MG cells (Fig 6) . Moreover, radiation did not significantly potentiate the growth inhibition of Adp53, even in A172 cells, where it increased Adp53-mediated apoptosis (Fig 3) .
DISCUSSION
Malignant brain tumors are ideal candidates for gene therapy because they only recur locally and rarely me- Flow cytometry was used to quantitate the apoptotic response of each treatment by measuring the sub-G 1 cell population. U373 MG cells underwent significant apoptosis after Adp53 infection. Although radiation had no effect on these cells, it potentiated the p53-induced apoptosis in A172 cells. U87 MG cells showed no nuclear fragmentation even when both agents were combined. Error bars represent SE. tastasize to other organs. At the present time, cancer gene therapy can be accomplished through either: (a) cytoreductive techniques, in which genes are delivered to interrupt cancer cell growth either directly via suicide genes or indirectly through immunomodulator genes, or (b) corrective gene therapy, in which defective or abnormal genes in neoplastic cells are inactivated or supplemented with genes that can reverse the loss of growthcontrol mechanisms. Tumor suppressor genes and antisense oncogenes are among the candidates for corrective gene therapy.
Inactivation of the p53 tumor suppressor gene may play a role in the tumorigenicity of most cancers. The p53 gene encodes a nuclear protein that binds to and modulates the expression of other genes that are important for DNA repair, 6 cell division, 19 and cell death by apoptosis. 20 Reconstitution of the p53 gene into p53 mut tumor cells may, therefore, lead to a re-establishment of these regulatory functions and may prove to be an effective antineoplastic strategy. Exogenous p53 gene expression has been found to induce apoptosis or sensitize p53-negative cells to DNAdamaging agents in several tumor models, including lung, 21 cervical, 22 prostate, 23 and head and neck tumors. 24, 25 In gliomas expressing p53 mut , Adp53 has been shown to induce apoptosis in vitro and partially inhibit tumor growth in vivo. 12, 13, 15, 16 When human glioma cells were transduced with Adp53 in vitro, most p53 mutexpressing cells showed significant apoptosis and growth suppression. Similarly, Gjerset et al 14 used Adp53 to induce apoptosis and sensitize T98G glioma cells (p53 mut ) to cisplatin in vitro. None of these studies, however, showed any apoptosis in p53 wt -expressing cells. Moreover, some p53 mut cells, such as A172, were more resistant to such therapy. 15 In this study, we tested the possibility that p53 overexpression may increase the sensitivity of these Adp53-resistant cells to X-radiation.
Three glioma cell lines with variable p53 activities and responses to Adp53 were selected to investigate the role of Adp53 radiosensitization. In U373 MG cells (p53 mut ), Adp53 induced apoptosis and cell death within 48 hours of viral exposure. These observations were consistent with those reported previously. 15 This p53-mediated apoptosis was probably mediated through pathways independent of Bax, because no changes in the expression of this protein were detected. Although radiation alone did not induce apoptosis within this time frame, it did result in G 2 /M arrest, confirming the lack of p53 function as a G 1 /S checkpoint in this p53 mut cell line. Moreover, X-radiation significantly suppressed U373 MG growth in vitro. Whether this growth arrest was due to delayed radiation-mediated apoptosis that was not detected under these experimental conditions or due to the observed G 2 /M arrest cannot be concluded from our studies. Because most radiation-sensitive cells such as thymocytes and medulloblastomas undergo apoptosis within a few hours of radiation exposure, 20, 26 it is more likely that the observed G 2 /M arrest was responsible for this growth inhibition. The administration of radiation after p53 treatment in U373 MG cells did not potentiate apoptosis. This observation indicates either that p53 cannot act as a radiosensitizer in this cell line or perhaps that the apoptotic pathways were already saturated due to p53 expression. Adp53 treatment did, however, lead to G 1 arrest in nonapoptotic cells after X-radiation. This change in cell cycle profile was most likely due to p53-mediated p21 expression, which is known to play a role in the G 1 /S checkpoint. It is not clear why most transduced U373 MG cells underwent apoptosis while some were arrested in G 1 . It is possible that these responses are dependent upon the temporal relationship of X-radiation and p53 expression to the cell cycle.
In contrast to U373 MG cells, A172 cells, which also express p53 mut , demonstrated little apoptosis after Adp53 treatment. This Adp53 resistance has been reported previously by Gomez-Manzano et al 15 , who noted that A172 cells die 8 days after Adp53 exposure, compared with 3 days seen in the more sensitive U373 MG cells. Because we did not detect any apoptosis within 48 hours of exposure to Adp53, we believe that this growth suppression was, in part, due to p21-mediated G 1 arrest.
Following radiation (10 Gy), A172 cells demonstrated a 30% increase in G 1 cells and a 50% increase in G 2 /M cells. These cell cycle changes may have been a result of radiation-mediated p21 expression through a p53-independent mechanism that has been reported previously in another cell line. 27 Interestingly, p53 expression before X-radiation significantly increased the apoptotic response to radiation in this cell line. This increase in apoptosis, however, was not related to changes in Bax expression, and other mechanisms such as activation of CPP32␤ (caspase 3) may have played a role. 28 Moreover, this radiosensitization did not translate into further growth inhibition as detected by clonogenic assays, suggesting that activation of cell cycle checkpoints may be as important as apoptosis in determining the radiation sensitivity of gliomas. 29 As reported by others, 15, 16 U87 MG cells showed the least response to Adp53 treatment, probably due to lack of apoptosis and weak G 1 arrest. After X-radiation, U87 MG cells, like U373 MG cells, demonstrated a significant increase in G 2 /M arrest. This finding seemed to be in contrast to the G 1 arrest reported by Yount et al 30 in U87 MG cells expressing p53 wt but not in those with an inactivated p53 gene. The discrepancy in our findings could be explained by the fact that we did not detect any p53 up-regulation by these cells after radiation, confirming that expression of this gene is important for G 1 arrest. In fact, when both p53 and p21 were up-regulated by Adp53 transduction, this G 1 checkpoint function was re-established in these cells. Whether our U87 MG cells have additional defects in radiation-mediated p53 expression (such as a mutation in the ATM gene) needs to be investigated. Otherwise, our results are in agreement with Yount et al, who also failed to observe any radiation-induced apoptosis or any radiosensitization of U87 MG cells when p53 was reactivated. This finding suggests that Adp53 therapy may not be appropriate for p53 wt tumors under these conditions. We conclude that the response to combined Adp53 and radiation therapies may be variable among gliomas. This therapy may not be an effective treatment for p53 wt -expressing tumors, and its efficacy on p53 mut tumors may be limited not only by transduction efficiency and levels of p53 expression in vivo but also by the activation of other cell cycle regulatory and apoptotic machinery. 
